Cargando…

Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema

We designed a retrospective observational study to identify factors associated with ocular hypertension [OHTN, defined as intraocular pressure (IOP) > 25 mmHg] after intravitreal dexamethasone (IVD) implantation in diabetic macular edema (DME) patients. We measured IOP monthly after placement of...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Moon Young, Kwon, Jin-woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426405/
https://www.ncbi.nlm.nih.gov/pubmed/32792579
http://dx.doi.org/10.1038/s41598-020-70833-1
_version_ 1783570675769802752
author Choi, Moon Young
Kwon, Jin-woo
author_facet Choi, Moon Young
Kwon, Jin-woo
author_sort Choi, Moon Young
collection PubMed
description We designed a retrospective observational study to identify factors associated with ocular hypertension [OHTN, defined as intraocular pressure (IOP) > 25 mmHg] after intravitreal dexamethasone (IVD) implantation in diabetic macular edema (DME) patients. We measured IOP monthly after placement of an IVD implant, and identified the trend of IOP, incidence of OHTN, and its associated systemic or ocular factors. On average, IOP was highest at 2 months after IVD implantation. Of 84 DME patients who received an IVD implant, 3 (3.57%) presented with an IOP ≥ 25 mmHg at 1 month after implantation, 6 (7.14%) at 2 months, and 2 (2.38%) at 3 months. Compared with the non-OHTN group, the OHTN group had significantly shorter axial lengths and were younger. Logistic regression analysis revealed that axial length < 23.00 mm and age < 57 years were associated with OHTN occurrence. Patients whose IOP was elevated > 30% or ≥ 20 mmHg at 1 month post-implantation, subsequently developed OHTN with statistical significance. In conclusion, shorter axial length and younger age were associated with OHTN occurrence after IVD implantation. Additionally, identifying levels or trends in IOP at 1 month after the IVD procedure may be helpful in predicting subsequent OHTN occurrence.
format Online
Article
Text
id pubmed-7426405
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-74264052020-08-14 Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema Choi, Moon Young Kwon, Jin-woo Sci Rep Article We designed a retrospective observational study to identify factors associated with ocular hypertension [OHTN, defined as intraocular pressure (IOP) > 25 mmHg] after intravitreal dexamethasone (IVD) implantation in diabetic macular edema (DME) patients. We measured IOP monthly after placement of an IVD implant, and identified the trend of IOP, incidence of OHTN, and its associated systemic or ocular factors. On average, IOP was highest at 2 months after IVD implantation. Of 84 DME patients who received an IVD implant, 3 (3.57%) presented with an IOP ≥ 25 mmHg at 1 month after implantation, 6 (7.14%) at 2 months, and 2 (2.38%) at 3 months. Compared with the non-OHTN group, the OHTN group had significantly shorter axial lengths and were younger. Logistic regression analysis revealed that axial length < 23.00 mm and age < 57 years were associated with OHTN occurrence. Patients whose IOP was elevated > 30% or ≥ 20 mmHg at 1 month post-implantation, subsequently developed OHTN with statistical significance. In conclusion, shorter axial length and younger age were associated with OHTN occurrence after IVD implantation. Additionally, identifying levels or trends in IOP at 1 month after the IVD procedure may be helpful in predicting subsequent OHTN occurrence. Nature Publishing Group UK 2020-08-13 /pmc/articles/PMC7426405/ /pubmed/32792579 http://dx.doi.org/10.1038/s41598-020-70833-1 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Choi, Moon Young
Kwon, Jin-woo
Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema
title Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema
title_full Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema
title_fullStr Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema
title_full_unstemmed Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema
title_short Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema
title_sort risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426405/
https://www.ncbi.nlm.nih.gov/pubmed/32792579
http://dx.doi.org/10.1038/s41598-020-70833-1
work_keys_str_mv AT choimoonyoung riskfactorsforocularhypertensionafterintravitrealdexamethasoneimplantationindiabeticmacularedema
AT kwonjinwoo riskfactorsforocularhypertensionafterintravitrealdexamethasoneimplantationindiabeticmacularedema